UK markets closed

Biocartis Group NV (BIOGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
5.200.00 (0.00%)
As of 5:07PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.20
Open5.20
BidN/A x N/A
AskN/A x N/A
Day's range5.20 - 5.20
52-week range5.20 - 5.20
Volume2,000
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Press release Biocartis Group NV: Results of the Extraordinary Shareholders’ Meeting held on 4 June 2021

    PRESS RELEASE: REGULATED INFORMATION4 June 2021, 17:40 CESTResults of the Extraordinary Shareholders’ Meeting held on 4 June 2021 Mechelen, Belgium, 4 June 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its extraordinary shareholders' meeting today. The shareholders approved all items on the agenda of the extraordinary shareholders' meeting. All documents relating to the shareholders’ meeting can be consulted

  • Globe Newswire

    Press release Biocartis Group NV: Invitation to the Extraordinary Shareholders’ Meeting

    PRESS RELEASE: REGULATED INFORMATION 17 May 2021, 07:00 CEST Invitation to the Extraordinary Shareholders’ Meeting Mechelen, Belgium, 17 May 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to a new extraordinary shareholders' meeting that will be held on Friday 4 June 2021 at 10:00 a.m. CEST. The legally required attendance quorum to validly deliberate and vote on the agenda items of the extraordinary shareholders' meeting held on 14 May 2021 was not reached. In light of the COVID-19 pandemic, it is currently envisaged that the measures imposed by the Belgian government to deal with this pandemic, such as the limitations on the number of people attending gatherings and the obligation to guarantee a distance of 1.5 meters between each person, may still be in effect on 4 June 2021, the date of the Company's extraordinary shareholders' meeting. These measures are in the interest of the health of individual securities holders, as well as of the employees of the Company and others who are responsible for organizing the extraordinary shareholders' meeting. Furthermore, it cannot be excluded that the Belgian government will impose additional measures. Hence, the Company advises its securities holders not to attend the extraordinary shareholders' meeting in person. Shareholders can exercise their voting rights by voting by mail form or by written proxy to the chairman of the Board of Directors of the Company. Furthermore, the Company recommends its securities holders to exercise their right to ask questions with respect to the agenda items of the extraordinary shareholders' meeting in writing, before the extraordinary shareholders' meeting. More information about voting by mail or by written proxy and exercising the right to ask questions can be found in the convening notice. Biocartis will monitor the COVID-19 situation closely and will disclose all relevant information and measures that have an impact on the extraordinary shareholders' meeting on the Biocartis website. Depending on the situation and the possibilities provided for by the applicable legislation, the Company reserves the right to take additional measures. The Board of Directors would like to thank the securities holders for their understanding and cooperation. In order to be admitted to the extraordinary shareholders’ meeting, the holders of securities issued by the Company must comply with Article 7:134 of the Belgian Code of Companies and Associations and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the extraordinary shareholders’ meeting can be consulted on the Company’s website. --- END --- More information: Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 About Biocartis Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_. Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. Forward-looking statementsCertain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

  • Globe Newswire

    Press release Biocartis Group NV: Results of the Shareholders’ Meetings held on 14 May 2021

    PRESS RELEASE: REGULATED INFORMATION14 May 2021, 17:40 CESTResults of the Shareholders’ Meetings held on 14 May 2021 Mechelen, Belgium, 14 May 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual and extraordinary shareholders' meetings today. The shareholders approved all items on the agenda of the annual shareholders' meeting. However, there was no deliberation and voting on the items on the agenda of the extraordinary shareholders’ meeting because the attendance quorum for such meeting was not reached. Biocartis will convene a second extraordinary shareholders’ meeting with the same agenda items, for which no attendance quorum will apply. All documents relating to the shareholders’ meetings can be consulted on the website of the Company. ----- END ---- More information: Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729 mobile +32 471 53 60 64 About Biocartis Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_. Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. Forward-looking statementsCertain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.